Anti-NMDAR encephalopathy

Treatment

Shigeaki Suzuki, Morinobu Seki, Norihiro Suzuki

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Anti-NMDAR encephalopathy is included in paraneoplastic limbic encephalopathy and show the good response to treatment compared to other paraneoplastic syndromes. Treatment of anti-NMDAR encephalopathy includes immunotherapy and/or tumor removal. About 65% of patients with anti-NMDAR encephalopathy had fully or near-full recovery. Immunotherapy is principally necessary and effective in patients with and without tumor. Corticosteroids and intravenous immunoglobulin are most frequently used. It is likely that patients who do not respond to one form of immunotherapy might respond to others regimens including plasmapheresis, cyclophosphamide, and rituximab. A tumor was found in 58% of patients with anti-NMDAR encephalopathy. Early removal of tumor should be considered based on following reasons. First, patients with ovarian teratoma showed higher mortality and higher titer of anti-NMDAR antibody compared with those without. Second, relapsing neurological symptoms occurred in 13% of patients, usually related to a delay in tumor diagnosis. Third, when a tumor was found and removed, recovery was faster and predictable. However, early removal of tumor cannot be conducted because of unstable conditions such as hypoventilation and dyskinesias. In supportive cares, severe central hypoventilation requires mechanical ventilation. The involuntary movements and facial dyskinesias are refractory to anti-epileptic drugs. In conclusion, search for and removal of an ovarian teratoma should be promptly considered after the diagnosis of anti-NMDAR encephalopathy.

Original languageEnglish
Pages (from-to)923-925
Number of pages3
JournalClinical Neurology
Volume48
Issue number11
Publication statusPublished - 2008 Nov

Fingerprint

Brain Diseases
Dyskinesias
Neoplasms
Immunotherapy
Hypoventilation
Therapeutics
Paraneoplastic Syndromes
Plasmapheresis
Intravenous Immunoglobulins
Artificial Respiration
Cyclophosphamide
Anti-Idiotypic Antibodies
Adrenal Cortex Hormones
Mortality
Pharmaceutical Preparations

Keywords

  • Cell-surface antigen
  • Immunotherapy
  • Ovarian teratoma
  • Tumor removal

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Anti-NMDAR encephalopathy : Treatment. / Suzuki, Shigeaki; Seki, Morinobu; Suzuki, Norihiro.

In: Clinical Neurology, Vol. 48, No. 11, 11.2008, p. 923-925.

Research output: Contribution to journalArticle

Suzuki, S, Seki, M & Suzuki, N 2008, 'Anti-NMDAR encephalopathy: Treatment', Clinical Neurology, vol. 48, no. 11, pp. 923-925.
Suzuki, Shigeaki ; Seki, Morinobu ; Suzuki, Norihiro. / Anti-NMDAR encephalopathy : Treatment. In: Clinical Neurology. 2008 ; Vol. 48, No. 11. pp. 923-925.
@article{f615fc70c2b5438b830261b96fef3a3c,
title = "Anti-NMDAR encephalopathy: Treatment",
abstract = "Anti-NMDAR encephalopathy is included in paraneoplastic limbic encephalopathy and show the good response to treatment compared to other paraneoplastic syndromes. Treatment of anti-NMDAR encephalopathy includes immunotherapy and/or tumor removal. About 65{\%} of patients with anti-NMDAR encephalopathy had fully or near-full recovery. Immunotherapy is principally necessary and effective in patients with and without tumor. Corticosteroids and intravenous immunoglobulin are most frequently used. It is likely that patients who do not respond to one form of immunotherapy might respond to others regimens including plasmapheresis, cyclophosphamide, and rituximab. A tumor was found in 58{\%} of patients with anti-NMDAR encephalopathy. Early removal of tumor should be considered based on following reasons. First, patients with ovarian teratoma showed higher mortality and higher titer of anti-NMDAR antibody compared with those without. Second, relapsing neurological symptoms occurred in 13{\%} of patients, usually related to a delay in tumor diagnosis. Third, when a tumor was found and removed, recovery was faster and predictable. However, early removal of tumor cannot be conducted because of unstable conditions such as hypoventilation and dyskinesias. In supportive cares, severe central hypoventilation requires mechanical ventilation. The involuntary movements and facial dyskinesias are refractory to anti-epileptic drugs. In conclusion, search for and removal of an ovarian teratoma should be promptly considered after the diagnosis of anti-NMDAR encephalopathy.",
keywords = "Cell-surface antigen, Immunotherapy, Ovarian teratoma, Tumor removal",
author = "Shigeaki Suzuki and Morinobu Seki and Norihiro Suzuki",
year = "2008",
month = "11",
language = "English",
volume = "48",
pages = "923--925",
journal = "Clinical Neurology",
issn = "0009-918X",
publisher = "Societas Neurologica Japonica",
number = "11",

}

TY - JOUR

T1 - Anti-NMDAR encephalopathy

T2 - Treatment

AU - Suzuki, Shigeaki

AU - Seki, Morinobu

AU - Suzuki, Norihiro

PY - 2008/11

Y1 - 2008/11

N2 - Anti-NMDAR encephalopathy is included in paraneoplastic limbic encephalopathy and show the good response to treatment compared to other paraneoplastic syndromes. Treatment of anti-NMDAR encephalopathy includes immunotherapy and/or tumor removal. About 65% of patients with anti-NMDAR encephalopathy had fully or near-full recovery. Immunotherapy is principally necessary and effective in patients with and without tumor. Corticosteroids and intravenous immunoglobulin are most frequently used. It is likely that patients who do not respond to one form of immunotherapy might respond to others regimens including plasmapheresis, cyclophosphamide, and rituximab. A tumor was found in 58% of patients with anti-NMDAR encephalopathy. Early removal of tumor should be considered based on following reasons. First, patients with ovarian teratoma showed higher mortality and higher titer of anti-NMDAR antibody compared with those without. Second, relapsing neurological symptoms occurred in 13% of patients, usually related to a delay in tumor diagnosis. Third, when a tumor was found and removed, recovery was faster and predictable. However, early removal of tumor cannot be conducted because of unstable conditions such as hypoventilation and dyskinesias. In supportive cares, severe central hypoventilation requires mechanical ventilation. The involuntary movements and facial dyskinesias are refractory to anti-epileptic drugs. In conclusion, search for and removal of an ovarian teratoma should be promptly considered after the diagnosis of anti-NMDAR encephalopathy.

AB - Anti-NMDAR encephalopathy is included in paraneoplastic limbic encephalopathy and show the good response to treatment compared to other paraneoplastic syndromes. Treatment of anti-NMDAR encephalopathy includes immunotherapy and/or tumor removal. About 65% of patients with anti-NMDAR encephalopathy had fully or near-full recovery. Immunotherapy is principally necessary and effective in patients with and without tumor. Corticosteroids and intravenous immunoglobulin are most frequently used. It is likely that patients who do not respond to one form of immunotherapy might respond to others regimens including plasmapheresis, cyclophosphamide, and rituximab. A tumor was found in 58% of patients with anti-NMDAR encephalopathy. Early removal of tumor should be considered based on following reasons. First, patients with ovarian teratoma showed higher mortality and higher titer of anti-NMDAR antibody compared with those without. Second, relapsing neurological symptoms occurred in 13% of patients, usually related to a delay in tumor diagnosis. Third, when a tumor was found and removed, recovery was faster and predictable. However, early removal of tumor cannot be conducted because of unstable conditions such as hypoventilation and dyskinesias. In supportive cares, severe central hypoventilation requires mechanical ventilation. The involuntary movements and facial dyskinesias are refractory to anti-epileptic drugs. In conclusion, search for and removal of an ovarian teratoma should be promptly considered after the diagnosis of anti-NMDAR encephalopathy.

KW - Cell-surface antigen

KW - Immunotherapy

KW - Ovarian teratoma

KW - Tumor removal

UR - http://www.scopus.com/inward/record.url?scp=63849222956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63849222956&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 923

EP - 925

JO - Clinical Neurology

JF - Clinical Neurology

SN - 0009-918X

IS - 11

ER -